Association Between Polymorphisms Of ERRC1and Chemotherapy Response In Patients With Lung Squamous Carcinoma Receiving Platinum-based Chemotherapy

Objective:To asses the association between single nucleotide polymorphisms OfC8092A and codon118in ERCC1and drug response in patients with lungsquamous carcinoma treated with Platinum-based chemotherapyMethodsWe investigated whether ERCC1gene polymorphism has an effect on theresponse to chemotherapyl in80patients with lung squamous carcinoma treatedwith platinum-based chemotherapy. ERCC1SNPs were assessed using aPCR-RFLP(Polymerase chain reaction—based restriction fragment lengthpolymorphism) method in DNA isolated from peripheral blood lymphocytes.ResultsGenotype frequencies of ERCC1C8092A were CC27．5％(22／80)，CA40．0％(32／80) and AA32．5％(26／80)，frequencies of codon l18wereCC33．8％(27／80)，CT36．2％(29／80) and TI30.0％(24／80)．There was nosignificant difference in response rate of patients carrying with CC compared withCA plus AA in C8092A(54.5%vs36.2%，P=0.13)．There was no significantdifference in response rate of patients carrying with CC compared with CT plusTT in C118T(37.0%vs43.4%，P=0.58)．There was no difference in Progressionfree survival between patients carrying with CC and CA plus AA in C8092A(4months vs5months，P=0.34)．There was no difference in Progression freesurvival between patients carrying with CC and CT plus TT(5months vs5months，P=0.49).Multivariate analysis of Cox proportional hazard model showedthat ERCC1C8092A(Hazard ratio=0．910， P=0．733) and codon118polymorphism(Hazard ratio=1．101，P=0．707) were not independently associatedwith the prognosis. ERCC1C8092A and codon118polymorphism were notcorrelated with sex，age，smoking and stage.Conclusion1. The results suggest that there may be no association between polymorphisms in ERCC1C8092A and codon l18and response in patients withlung squamous carcinoma receiving cisplatin-based chemotherapy．2. there may be no association between polymorphisms in ERCC1C8092Aand codon l18and the Progression free survival in patients with lung squamouscarcinoma receiving cisplatin-based chemotherapy．3. ERCC1C8092A and codon118polymorphism were not correlated withsex，age，smoking and stage.